Shou-Ching Jaminet

Company: Angiex Inc

Job title: Founder

Seminars:

TM4SF1: An Attractive Vascular & Tumor Cell Target for Solid Tumor Therapy 12:30 pm

TM4SF1 is a novel and attractive target for solid tumor therapy TM4SF1 offers a unique payload delivery mechanism for antibody-drug-conjugates (ADCs) TM4SF1 ADCs may be a favorable method for delivering STING agonists in solid tumorsRead more

day: Innate Immune Checkpoints & Activation Pre-Conference Focus Day